Michael J Detke MD PhD
Psychopharmacology
Gereral outpatient part-time at Indiana University School of Medicine (Clinical Associate Professor)
Join to View Full Profile
5018 Saint Charles PlCarmel, IN 46033
Phone+1 317-902-2002
Dr. Detke is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Mass General Brigham/Massachusetts General Hospital/McLean HospitalResidency, Psychiatry, 1996 - 2000
University of PennsylvaniaPhD, Psychology, 1988 - 1998
Perelman School of Medicine at the University of PennsylvaniaClass of 1996
Certifications & Licensure
IN State Medical License 2000 - 2025
American Board of Psychiatry and Neurology Psychiatry
Publications & Presentations
PubMed
- 45 citationsMeasures of outcome for stimulant trials: ACTTION recommendations and research agendaBrian D. Kiluk, Kathleen M. Carroll, Amy M. Duhig, Daniel E. Falk, Kyle M. Kampman
Drug and Alcohol Dependence. 2016-01-01 - 5 citationsComparison of Site-Based Versus Central Ratings in a Study of Generalized Anxiety Disorder.Janet B. W. Williams, Kenneth A. Kobak, Earl L. Giller, David S. Reasner, Lisa Curry
Journal of Clinical Psychopharmacology. 2015-12-01 - 47 citationsA 6-week randomized, double-blind, placebo-controlled, comparator referenced trial of vabicaserin in acute schizophreniaJoan H.Q. Shen, Yonggang Zhao, Sharon Rosenzweig-Lipson, Danielle Popp, Janet B. W. Williams
Journal of Psychiatric Research. 2014-06-01
Press Mentions
Lighthouse Pharmaceuticals Announces Progression of LHP588 Clinical Development Program in Alzheimer's DiseaseMay 10th, 2023- Cortexyme, SQZ, Others Present New Insights into Alzheimer's and Parkinson'sMarch 21st, 2022
- Cortexyme Provides New GAIN Trial Data at AD/PD 2022 Demonstrating Potential Benefit of Lysine Gingipain Inhibition in Mild to Moderate Alzheimer’s PopulationMarch 21st, 2022
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
